Evidence map›Paper›PMID 26192161›Full record

ArticleTissue engineering. Part B, Reviews2016

A Road Map to Commercialization of Cartilage Therapy in the United States of America.

BanuPriya Sridharan, Blanka Sharma, Michael S Detamore

Abstract read
In one paragraph

Article in Tissue engineering. Part B, Reviews, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Developing anFrontiers in immunology · 2025
    Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Biomaterials to Mimic and Heal Connective Tissues.Advanced materials (Deerfield Beach, Fla.) · 2019
    Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

BanuPriya Sridharan1 Bioengineering Program, University of Kansas , Lawrence, Kansas.
Blanka Sharma2 Department of Biomedical Engineering, University of Florida , Gainesville, Florida.
Michael S Detamore1 Bioengineering Program, University of Kansas , Lawrence, Kansas.

Funding

Gradient-based strategy for osteochondral regenerationR01AR056347 · NIAMS · UNIVERSITY OF KANSAS LAWRENCE · PI DETAMORE, MICHAEL S. · 2010 to 2014
$1.3M
NIAMS NIH HHS R01 AR056347
6 · The paper itself

Abstract

Despite numerous efforts in cartilage regeneration, few products see the light of clinical translation as the commercialization process is opaque, financially demanding, and requires collaboration with people of varied skill sets. The aim of this review is to introduce, to an academic audience, the different paradigms involved in the commercialization of cartilage regeneration technology, elucidate the different hurdles associated with the use of cells and materials in developing new technologies, discuss potential commercialization strategies, and inform the reader about the current trends observed in both the clinical and laboratory setting for establishing clinical trials. Although there are review articles on articular cartilage tissue engineering, independent reports provided by the Food and Drug Administration, and separate review articles on animal models, this is the first review that encompasses all of these facets and is presented in a format favorable to the academic investigator interested in clinical translation from bench to bedside.

Identifiers

PMID26192161
PMCPMC4753577

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.